A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.

@article{Gray2017ARP,
  title={A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.},
  author={Kevin M Gray and Susan C. Sonne and Erin A. McClure and Udi E Ghitza and Abigail G. Matthews and Aimee L. McRae-Clark and Kathleen M. Carroll and Jennifer Sharpe Potter and Katharina L. Wiest and Larissa J Mooney and Albert L. Hasson and Sharon L. Walsh and Michelle R. Lofwall and Shanna Babalonis and Robert W. Lindblad and Steven Sparenborg and Aimee Wahle and Jacqueline S King and Nathaniel L. Baker and Rachel L Tomko and Louise F Haynes and Ryan Vandrey and Frances R. Levin},
  journal={Drug and alcohol dependence},
  year={2017},
  volume={177},
  pages={
          249-257
        }
}
BACKGROUND Cannabis use disorder (CUD) is a prevalent and impairing condition, and established psychosocial treatments convey limited efficacy. In light of recent findings supporting the efficacy of N-acetylcysteine (NAC) for CUD in adolescents, the objective of this trial was to evaluate its efficacy in adults. METHODS In a 12-week double-blind randomized placebo-controlled trial, treatment-seeking adults ages 18-50 with CUD (N=302), enrolled across six National Drug Abuse Treatment Clinical… Expand
Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder
TLDR
Depression may be a risk factor for poor CUD treatment outcome and therefore should be addressed in the context of treatment, but results do not support the use of NAC to concurrently treat co-occurring depressive symptoms and CUD in adults. Expand
The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial.
TLDR
It is indicated that NAC may be effective at reducing consumption of alcohol by ∼30% among treatment-seeking adults with CUD, suggesting a need for further trials focused on the effects of NAC on alcohol consumption among individuals seeking treatment for AUD. Expand
Evaluating N-acetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers.
TLDR
Results indicate that NAC is a well-tolerated pharmacotherapy but is unlikely to be efficacious as a monotherapy for TUD in adults. Expand
Effectiveness of N-acetylcysteine in Treating Clinical Symptoms of Substance Abuse and Dependence: A Meta-analysis of Randomized Controlled Trials
TLDR
NAC provides certain noticeable benefits in attenuating substance craving and might help alleviate depressive symptoms and withdrawal syndrome and Precautious measures should be considered when using NAC although no difference in adverse effects was found between NAC treatment and control group. Expand
N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial
TLDR
Take-home oral NAC has no significant effect on methamphetamine use or most clinically related outcomes amongst people who are dependent on the drug, and does not significantly reduce craving, severity of dependence, withdrawal, suicidality, depression, hostility or psychotic symptoms relative to placebo. Expand
Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study
TLDR
Nabilone pharmacotherapy was safe and well-tolerated in participants with cannabis dependence and remains a candidate for additional pharmacotherapy trials for cannabis dependence. Expand
The role of depressive symptoms in treatment of adolescent cannabis use disorder with N-Acetylcysteine.
Relative to adults, adolescents are at greater risk of developing a cannabis use disorder (CUD) and risk may be exacerbated by co-occurring depressive symptoms. N-Acetylcysteine (NAC), anExpand
Relative effectiveness of N-acetylcysteine and baclofen as anticraving agents in cannabis dependence – A retrospective study with telephonic follow-up
TLDR
The use of anticraving medications, namely BAC and NAC, may be a useful option along with PSIs in patients with cannabis dependence and requires further exploration. Expand
Quetiapine treatment for cannabis use disorder.
TLDR
The use of quetiapine to treat CUD was associated with an increased likelihood of heavy frequency use transitioning to moderate use, but not light use, and the clinical significance of reductions in cannabis use, short of abstinence warrants further study. Expand
N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence
TLDR
Current evidence supports N-acetylcysteine use as an adjunctive therapy clinically for psychiatric conditions, administered concomitantly with existing medications, with a recommended dosage between 2000 and 2400 mg/day. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 35 REFERENCES
A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents.
TLDR
This is the first randomized controlled trial of pharmacotherapy for cannabis dependence in any age group to yield a positive primary cessation outcome in an intent-to-treat analysis, and findings support NAC as a pharmacotherapy to complement psychosocial treatment for Cannabis dependence in adolescents. Expand
Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network.
TLDR
This study was designed to replicate positive findings from a study in cannabis-dependent adolescents that found greater odds of abstinence with NAC compared to PBO, and will assess the cannabis cessation efficacy of NAC combined with a behavioral intervention in adults, providing a novel and timely contribution to the evidence base for the treatment of cannabis use disorders. Expand
Topiramate for treating alcohol dependence: a randomized controlled trial.
TLDR
Topiramate is a promising treatment for alcohol dependence and can improve drinking outcomes among alcohol-dependent individuals by reducing alcohol's reinforcing effects through facilitation of gamma-aminobutyric acid function and inhibition of glutaminergic pathways in the corticomesolimbic system. Expand
Pharmacotherapies for cannabis dependence.
TLDR
There was no difference in the likelihood of withdrawal from treatment due to adverse effects with THC preparations, SSRIs antidepressants, mixed action antidepressants, anticonvulsants and mood stabilisers, buspirone and N-acetylcysteine compared to placebo (low- to very low-quality evidence), and abstinence at end of treatment was no more likely than with placebo. Expand
Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence.
TLDR
The results suggest that busPirone is unlikely to have a beneficial effect on preventing relapse to cocaine use and that buspirone for cocaine-dependent women may worsen their cocaine use outcomes. Expand
Potential Role of N-Acetylcysteine in the Management of Substance Use Disorders
TLDR
This review will focus specifically on N-acetylcysteine (NAC), a safe and well-tolerated glutamatergic agent, as a promising potential pharmacotherapy for the treatment of SUDs across several substances of abuse. Expand
A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence.
TLDR
Pergolide does not appear to have clinical value in the treatment of cocaine dependence or in decreasing alcohol use in cocaine-dependent individuals at the presently studied doses. Expand
A randomized controlled trial of auricular acupuncture for cocaine dependence.
TLDR
Findings from the current study suggest that acupuncture shows promise for the treatment of cocaine dependence. Expand
Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review
TLDR
Evidence has shown a decrease in the age of commencement of cannabis use in some developed countries and a prolongation of risk of initiation to cannabis use beyond adolescence among more recent users. Expand
Moderating effects of race in clinical trial participation and outcomes among marijuana-dependent young adults.
TLDR
Findings suggest that clinical trial treatment and posttreatment completion rates vary by race in this population, as does response to specific treatment types, and more treatment research focusing specifically on African American marijuana-dependent young adults is warranted. Expand
...
1
2
3
4
...